Vaccines for Latent Viral Infections

Vaccines for Latent Viral Infections

Indexed in: EBSCO

Many viruses are known to persist in their host’s cells in a latent state without exhibiting virulence or symptoms of infection, hence, giving rise to the term ‘latent infections’. Vaccines for ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



Epstein-Barr Virus Infections and Vaccine Advances

Pp. 71-97 (27)

DOI: 10.2174/9781681081328115010009

Author(s): Risaku Fukumoto

Abstract

Epstein-Barr virus (EBV) infection is associated with a spectrum of fatal diseases including Burkitt’s lymphoma (BL) and nasopharyngeal carcinoma (NPC). Higher incidence of BL and NPC seen in developing world demands an effective vaccine to prevent infection and disease onset. EBV primarily infects people during infant or adolescent ages and establishes latent infection. Vast majority of EBVassociated diseases develop later in immune-compromised individuals, suggesting the link between host immunity and viral reactivation. This chapter discusses viral factors that EBV produces whose interactions with host may determine infection, reactivation, immune evasion and disease progression, and further reviews vaccine formulations tested to date. Knowledge in such viral factors is indispensable for vaccine advances.

Keywords:

Epstein-Barr virus, Burkitt’s lymphoma, viral factors, latent infection, nasopharyngeal carcinoma, Herpesviridae, Gammaherpesvirinae, B cells, infectious mononucleosis, EBNA, LMP, lytic phase, latency, EBER, BCRF1, BHRF1, BZLF1, gp350, gp220, virus